|Bid||85.91 x 900|
|Ask||85.90 x 1300|
|Day's range||84.36 - 86.26|
|52-week range||78.29 - 100.15|
|Beta (3Y monthly)||0.69|
|PE ratio (TTM)||24.28|
|Earnings date||23 May 2019|
|Forward dividend & yield||2.00 (2.20%)|
|1y target est||103.28|
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
The MedTech Innovation Accelerator is a collaborative initiative on part of Medtronic (MDT) to foray into the Chinese med-tech innovation market via venture investments, incubation and acceleration.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulatedRead More...
The U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulnerabilities were identified in Medtronic Plc's implantable cardiac devices, clinic programmers, and home monitors. Last year, Medtronic disabled internet updates for some 34,000 CareLink programming devices that healthcare providers around the world use to access implanted pacemakers, saying the system was vulnerable to cyberattacks.
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
On 25 January 2019, Medtronic plc (NYSE:MDT) released its earnings update. Generally, analysts seem cautiously optimistic, as a 19% increase in profits is expected in the upcoming year, relative toRead More...
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
We are upbeat about the recently-concluded buyout of Mazor Robotics, which is likely to solidify Medtronic's (MDT) position in the spine surgery space.